Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
C Michael Gibson, Danielle Duffy, Serge Korjian, M Cecilia Bahit, Gerald Chi, John H Alexander, A Michael Lincoff, Mark Heise, Pierluigi Tricoci, Lawrence I Deckelbaum, Sojaita Jenny Mears, Jose C Nicolau, Renato D Lopes, Bela Merkely, Basil S Lewis, Jan H Cornel, Jaroslaw Trebacz, Alexander Parkhomenko, Peter Libby, Frank M Sacks, Thomas J Povsic, Marc Bonaca, Shaun G Goodman, Deepak L Bhatt, Michal Tendera, P Gabriel Steg, Paul M Ridker, Philip Aylward, John J P Kastelein, Christoph Bode, Kenneth W Mahaffey, Stephen J Nicholls, Stuart J Pocock, Roxana Mehran, Robert A Harrington
BACKGROUND: Cardiovascular events frequently recur after acute myocardial infarction, and low cholesterol efflux - a process mediated by apolipoprotein A1, which is the main protein in high-density lipoprotein - has been associated with an increased risk of cardiovascular events. CSL112 is human apolipoprotein A1 derived from plasma that increases cholesterol efflux capacity. Whether infusions of CSL112 can reduce the risk of recurrent cardiovascular events after acute myocardial infarction is unclear...
April 6, 2024: New England Journal of Medicine
#22
EDITORIAL
Jean Rouleau
No abstract text is available yet for this article.
April 6, 2024: New England Journal of Medicine
#23
EDITORIAL
Christie M Ballantyne, Vijay Nambi
No abstract text is available yet for this article.
April 6, 2024: New England Journal of Medicine
#24
JOURNAL ARTICLE
Javed Butler, W Schuyler Jones, Jacob A Udell, Stefan D Anker, Mark C Petrie, Josephine Harrington, Michaela Mattheus, Isabella Zwiener, Offer Amir, M Cecilia Bahit, Johann Bauersachs, Antoni Bayes-Genis, Yundai Chen, Vijay K Chopra, Gemma Figtree, Junbo Ge, Shaun G Goodman, Nina Gotcheva, Shinya Goto, Tomasz Gasior, Waheed Jamal, James L Januzzi, Myung Ho Jeong, Yuri Lopatin, Renato D Lopes, Béla Merkely, Puja B Parikh, Alexander Parkhomenko, Piotr Ponikowski, Xavier Rossello, Morten Schou, Dragan Simic, P Gabriel Steg, Joanna Szachniewicz, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L Bhatt, Adrian F Hernandez
BACKGROUND: Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The safety and efficacy of empagliflozin in patients who have had acute myocardial infarction are unknown. METHODS: In this event-driven, double-blind, randomized, placebo-controlled trial, we assigned, in a 1:1 ratio, patients who had been hospitalized for acute myocardial infarction and were at risk for heart failure to receive empagliflozin at a dose of 10 mg daily or placebo in addition to standard care within 14 days after admission...
April 6, 2024: New England Journal of Medicine
#25
JOURNAL ARTICLE
Mikhail N Kosiborod, Mark C Petrie, Barry A Borlaug, Javed Butler, Melanie J Davies, G Kees Hovingh, Dalane W Kitzman, Daniél V Møller, Marianne B Treppendahl, Subodh Verma, Thomas J Jensen, Karoline Liisberg, Marie L Lindegaard, Walter Abhayaratna, Fozia Z Ahmed, Tuvia Ben-Gal, Vijay Chopra, Justin A Ezekowitz, Michael Fu, Hiroshi Ito, Małgorzata Lelonek, Vojtěch Melenovský, Bela Merkely, Julio Núñez, Eduardo Perna, Morten Schou, Michele Senni, Kavita Sharma, Peter van der Meer, Dirk Von Lewinski, Dennis Wolf, Sanjiv J Shah
BACKGROUND: Obesity and type 2 diabetes are prevalent in patients with heart failure with preserved ejection fraction and are characterized by a high symptom burden. No approved therapies specifically target obesity-related heart failure with preserved ejection fraction in persons with type 2 diabetes. METHODS: We randomly assigned patients who had heart failure with preserved ejection fraction, a body-mass index (the weight in kilograms divided by the square of the height in meters) of 30 or more, and type 2 diabetes to receive once-weekly semaglutide (2...
April 6, 2024: New England Journal of Medicine
#26
JOURNAL ARTICLE
Felippe O Marcondes, Emily Ling
New England Journal of Medicine, Volume 390, Issue 14, Page 1261-1263, April 2024.
April 6, 2024: New England Journal of Medicine
#27
JOURNAL ARTICLE
Joelle M Abi-Rached, Allan M Brandt
New England Journal of Medicine, Volume 390, Issue 13, Page 1157-1161, April 2024.
March 30, 2024: New England Journal of Medicine
#28
JOURNAL ARTICLE
Aletha Maybank
New England Journal of Medicine, Volume 390, Issue 14, Page 1258-1260, April 2024.
March 20, 2024: New England Journal of Medicine
#29
JOURNAL ARTICLE
Daniel P Sulmasy
New England Journal of Medicine, Volume 390, Issue 12, Page 1061-1063, March 21/28, 2024.
March 16, 2024: New England Journal of Medicine
#30
JOURNAL ARTICLE
Bryan D Choi, Elizabeth R Gerstner, Matthew J Frigault, Mark B Leick, Christopher W Mount, Leonora Balaj, Sarah Nikiforow, Bob S Carter, William T Curry, Kathleen Gallagher, Marcela V Maus
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects...
March 13, 2024: New England Journal of Medicine
#31
JOURNAL ARTICLE
David A Sacks, Marc H Incerpi
New England Journal of Medicine, Volume 390, Issue 11, Page 968-969, March 2024.
March 9, 2024: New England Journal of Medicine
#32
JOURNAL ARTICLE
Bao-Ping Xu, Xiao-Tao Wang
New England Journal of Medicine, Volume 390, Issue 11, March 2024.
March 9, 2024: New England Journal of Medicine
#33
JOURNAL ARTICLE
R Alta Charo
New England Journal of Medicine, Volume 390, Issue 14, Page 1253-1255, April 2024.
March 6, 2024: New England Journal of Medicine
#34
JOURNAL ARTICLE
Paul A Lombardo
New England Journal of Medicine, Volume 390, Issue 10, Page 869-873, March 2024.
March 2, 2024: New England Journal of Medicine
#35
JOURNAL ARTICLE
Arnold S Monto, Maria Zambon, Jerry P Weir
New England Journal of Medicine, Volume 390, Issue 14, Page 1256-1258, April 2024.
February 28, 2024: New England Journal of Medicine
#36
JOURNAL ARTICLE
Robert A Wood, Alkis Togias, Scott H Sicherer, Wayne G Shreffler, Edwin H Kim, Stacie M Jones, Donald Y M Leung, Brian P Vickery, J Andrew Bird, Jonathan M Spergel, Ahmar Iqbal, Julie Olsson, Monica Ligueros-Saylan, Alkaz Uddin, Agustin Calatroni, Charmaine Marquis Huckabee, Nicole H Rogers, Nancy Yovetich, Jennifer Dantzer, Kim Mudd, Julie Wang, Marion Groetch, David Pyle, Corinne A Keet, Michael Kulis, Sayantani B Sindher, Andrew Long, Amy M Scurlock, Bruce J Lanser, Tricia Lee, Christopher Parrish, Terri Brown-Whitehorn, Amanda K Rudman Spergel, Maria Veri, Sanaz Daneshfar Hamrah, Erica Brittain, Julian Poyser, Lisa M Wheatley, R Sharon Chinthrajah
BACKGROUND: Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. METHODS: In this trial, we assessed whether omalizumab, a monoclonal anti-IgE antibody, would be effective and safe as monotherapy in patients with multiple food allergies. Persons 1 to 55 years of age who were allergic to peanuts and at least two other trial-specified foods (cashew, milk, egg, walnut, wheat, and hazelnut) were screened...
February 25, 2024: New England Journal of Medicine
#37
JOURNAL ARTICLE
Timiya S Nolan, John Gregory, Joshua J Joseph
New England Journal of Medicine, Volume 390, Issue 9, Page 778-779, February 2024.
February 24, 2024: New England Journal of Medicine
#38
JOURNAL ARTICLE
Seth A Berkowitz, Jean Terranova
New England Journal of Medicine, Volume 390, Issue 9, Page 775-776, February 2024.
February 24, 2024: New England Journal of Medicine
#39
JOURNAL ARTICLE
Schenita D Randolph, Ragan Johnson
New England Journal of Medicine, Volume 390, Issue 9, Page 776-777, February 2024.
February 24, 2024: New England Journal of Medicine
#40
JOURNAL ARTICLE
Michael E Wechsler, Parameswaran Nair, Benjamin Terrier, Bastian Walz, Arnaud Bourdin, David R W Jayne, David J Jackson, Florence Roufosse, Lena Börjesson Sjö, Ying Fan, Maria Jison, Christopher McCrae, Sofia Necander, Anat Shavit, Claire Walton, Peter A Merkel
BACKGROUND: Eosinophilic granulomatosis with polyangiitis (EGPA) is a vasculitis characterized by eosinophilic inflammation. Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. METHODS: We conducted a multicenter, double-blind, phase 3, randomized, active-controlled noninferiority trial to evaluate the efficacy and safety of benralizumab as compared with mepolizumab. Adults with relapsing or refractory EGPA who were receiving standard care were randomly assigned in a 1:1 ratio to receive benralizumab (30 mg) or mepolizumab (300 mg) subcutaneously every 4 weeks for 52 weeks...
February 23, 2024: New England Journal of Medicine
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
